CVS/Aetna To Merge In Defensive Play To Reshape Healthcare Delivery

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

The pharmacy retail chain and drug distributor will buy the insurer for $69bn in a merger to build what the companies say will be a new, more affordable healthcare concept.

Female CVS retail pharmacist with patient

The pharmacy retail giant CVS Health Corp.'s purchase of health insurer Aetna Inc. in a $69bn merger will shake up the way drugs and healthcare are delivered. The companies say a more integrated healthcare management and delivery platform will help eliminate waste and make healthcare more affordable, while also presenting new opportunities through CVS' walk-in clinics to bring expanding healthcare options to patients.

The combination of two heavyweights working in different areas of the healthcare spectrum could present speed bumps in the near-term,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Supply Chain

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Nabil

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

India Pharma Chiefs On Supply Chain Learnings From Auto Sector, New ‘PAGE’ On Skilling

 
• By Anju Ghangurde

Leaders from India’s top drug makers discuss efforts to operationalize a world-class skilling institute, backed by tie-ups with organizations like the PDA, ISPE and also taking a leaf out of the automobile industry’s book to build supply chain resilience. They also exuded confidence on moving up the innovation value chain.

Moderna And GSK Hit By Declining RSV Vaccines Expectations

 
• By Andrew McConaghie

The efficacy of Moderna’s jab appears to fade faster than its rivals, while experts were surprised by an FDA panel’s recommendation to narrow the use of all three RSV vaccines.

Novo Dips Into Money Pile Again To Boost Obesity Drug Manufacturing

 
• By Kevin Grogan

The Danish drugmaker is investing over $4.1bn on a second facility in North Carolina for its GLP-1 therapies but has abandoned plans to build a new plant in Dublin, Ireland.

More from Business

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.